Moskowitz Eye Care

08/18/2026

Did you know we offer a gentle, non-invasive procedure that can help patients look younger on top of relieving dryness?

OptiLIFT™ uses Radiofrequency (RF) and Dynamic Muscle Stimulation (DMS) to tighten the lower eyelids and surrounding skin.

Learn about how it works in this new explainer!

Here’s how we help patients look younger with a non-invasive, in-office procedure called OptiLIFT. By Craig Moskowitz, MD

06/23/2026

LipiFlow is one of the best-known in-office treatments for Meibomian Gland Dysfunction (MGD). It helps, but it's only a one-time reset. It doesn't touch the inflammation, Demodex, or weak blink mechanics that caused the glands to clog in the first place.

In this blog, we walk through why OptiLIGHT IPL + OptiLIFT target and treat those upstream causes better than LipiFlow.

Visit https://moskowitz-eye.com/blog/ipl-vs-lipiflow-nyc for the full comparison!

Here's how to choose between two of the leading in-office Dry Eye Treatments in NYC By Craig Moskowitz, MD

04/29/2026

If you've been researching Photofacials in NYC, you've probably noticed that you can get them just about anywhere at this point – med spas, aesthetics studios, dermatology chains and so on.

The pitch is consistent: IPL (Intense Pulsed Light) reduces redness, clears uneven skin tone, smooths texture, and fades visible blood vessels.

All of that is true: Photofacials can meaningfully improve how your skin looks *and* effectively treat dry eye. 💡✅

What the med spa blogs and brochures don't tell you is that where you get this treatment done matters quite a bit.

Learn more here: https://moskowitz-eye.com/blog/photofacial-nyc

Skip the med spa and maximize the aesthetic benefits of IPL while eliminating the possibility of lackluster care or safety. Plus… it costs the same. By Craig Moskowitz, MD

03/30/2026

This story be a little esoteric for most people, but it's too interesting not to share...

Last Summer, one of our TikToks inexplicably went viral. We usually received 1,000-2,000 views for most of our educational LASIK/ASA videos, but this one skyrocketed to 2 MILLION within just a couple weeks (it now has 3.1 million views).

How and why this happened taught us a lot about social media virality and tracking, and reaffirmed even more about the dialogue happening across the social web about laser vision correction.

Hope you find it interesting! https://moskowitz-eye.com/blog/going-viral-lasik-tiktok

Reflecting about the time we got three million views and what it revealed about tracking and virality on the social web By Craig Moskowitz, MD

03/23/2026

So it turns out the may not be the future of digital connection after all...

From an eye care perspective, it's probably a good thing this $80B 💸 investment didn't quite pan out!

Here's a blog from the archives (February 2022).

Call it what you want – the rise of The Metaverse , Virtual Reality , Phygital Experiences, or Web 3.0 will pose major problems to your eyes in real life. By Dr. Craig Moskowitz

02/06/2026

Watching the big game Sunday 🏈📺??? Keep an 👁️ out for eye drop commercials...

The makers of Miebo and Xdemvy have spent millions on national campaigns advertising their products. And they're memorable spots, too! Chances are we’ll see one of these during the Super Bowl.

disease and have become increasingly prevalent and diagnosed problems.

So how do Miebo and Xdemvy compare to our new in-office OptiLIGHT™ treatment? I explain in this new blog:

By Craig Moskowitz, MD

01/20/2026

Dry eye care has evolved, and so have we! 👀👀

We now offer and , two state-of-the-art dry eye treatments that address the root causes of dryness and drooping.

These gentle 💫 in-office procedures use intense pulsed light and dynamic muscle stimulation to effectively relieve inflammation, blocked oil glands, and aging eyelids WITHOUT surgery or downtime. They offer meaningful cosmetic improvements without the invasiveness of surgery and super high cost of other aesthetic procedures.

If your eyes often feel dry, irritated, or tired even after trying drops, give this a read!

Press Release // Syndicated on January 20, 2026

01/20/2026